Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Molecular Assay System Validated for Opportunistic Virus Infections

By LabMedica International staff writers
Posted on 31 Oct 2012
Laboratory-developed real-time polymerase chain reaction (PCR) protocols have been implemented for the molecular diagnosis of opportunistic DNA virus infections. More...


The validity of a duplex real-time PCR protocols for viral DNA have been improved by using an extraction and amplification control that allows for the monitoring of the molecular diagnostic process.

Virologists at the Pierre and Marie Curie University (Paris, France) tested 152 clinical samples including 77 whole bloods, 30 bronchoalveolar lavages, 28 viral transport medium containing mucocutaneous swabs, 12 urine, and 5 stool samples. The genomes of herpes simplex virus (HSV), varicella-zoster virus (VZV), human cytomegalovirus (CMV), Epstein–Barr virus (EBV), BK virus (BKV), and adenovirus (AdV) were investigated.

The Simplexa extraction and amplification control (SEAC) set (Eurobio; Courtaboeuf, France) was evaluated in this study. This internal control corresponds to a 577-base pair DNA fragment derived from the gene encoding ribulose-1,5-bisphosphate carboxylase oxygenase large unit N-methyltransferase of the plant Arabidopsis thaliana. This is a noncompetitive internal control with its own mix, containing primers and a Quasar 670 labeled-probe specifically designed for its amplification (Biosearch Technologies; Novato, CA, USA). Viral DNA amplifications were performed on the Light cycler LC480 system (Roche Diagnostics; Meylan, France) using laboratory-developed real-time PCR assays based on hydrolysis probe technology implemented in the laboratory for virological diagnosis activity.

The SEAC results showed high reproducibility with a mean crossing point (Cp) value of 31.08 ± 1.44, and were not influenced by the virus-specific PCR performed or the type of clinical specimen tested. The use of the SEAC did not influence the results of the different virus-specific PCRs compared to other systems. The SEAC in the DNA extracts showed high stability during storage at both +4 °C and -20 °C.

The authors concluded that the use of the commercial SEAC is simple, straightforward, and beneficial. It makes not only the detection of opportunistic viruses in clinical samples more convenient and cost-effective, but it ensures also the effectiveness of the whole molecular process implemented in the laboratory to perform the diagnosis of viral infections. The SEAC provides a reliable option to improve the diagnosis of opportunistic viral infections in laboratories using in-house real-time PCR assays. The study was published in the October 2012 edition of the Journal of Virological Methods.

Related Links:
Pierre and Marie Curie University
Eurobio
Biosearch Technologies


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.